388 related articles for article (PubMed ID: 26870930)
41. Role of cenicriviroc in the management of nonalcoholic fatty liver disease.
Neokosmidis G; Tziomalos K
World J Gastroenterol; 2018 Dec; 24(48):5415-5417. PubMed ID: 30622370
[TBL] [Abstract][Full Text] [Related]
42. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases.
Lemoinne S; Friedman SL
Curr Opin Pharmacol; 2019 Dec; 49():60-70. PubMed ID: 31590120
[TBL] [Abstract][Full Text] [Related]
43. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.
Sanyal AJ; Friedman SL; McCullough AJ; Dimick-Santos L; ;
Hepatology; 2015 Apr; 61(4):1392-405. PubMed ID: 25557690
[TBL] [Abstract][Full Text] [Related]
44. Antifibrotic Therapies: Where Are We Now?
Yoon YJ; Friedman SL; Lee YA
Semin Liver Dis; 2016 Feb; 36(1):87-98. PubMed ID: 26870935
[TBL] [Abstract][Full Text] [Related]
45. Repurposing drugs to target nonalcoholic steatohepatitis.
Sookoian S; Pirola CJ
World J Gastroenterol; 2019 Apr; 25(15):1783-1796. PubMed ID: 31057294
[TBL] [Abstract][Full Text] [Related]
46. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
Musso G; Cassader M; Paschetta E; Gambino R
Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
[TBL] [Abstract][Full Text] [Related]
47. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
Drenth JPH; Schattenberg JM
Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035
[TBL] [Abstract][Full Text] [Related]
48. Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?
Gehrke N; Schattenberg JM
Gastroenterology; 2020 May; 158(7):1929-1947.e6. PubMed ID: 32068022
[TBL] [Abstract][Full Text] [Related]
49. NASH: A glance at the landscape of pharmacological treatment.
Brodosi L; Marchignoli F; Petroni ML; Marchesini G
Ann Hepatol; 2016; 15(5):673-81. PubMed ID: 27493105
[TBL] [Abstract][Full Text] [Related]
50. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
51. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
[TBL] [Abstract][Full Text] [Related]
52. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.
Filozof C; Goldstein BJ; Williams RN; Sanyal A
Drugs; 2015 Aug; 75(12):1373-92. PubMed ID: 26201461
[TBL] [Abstract][Full Text] [Related]
53. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.
Qiu LX; Chen T
World J Gastroenterol; 2015 Jan; 21(4):1099-107. PubMed ID: 25632182
[TBL] [Abstract][Full Text] [Related]
54. Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis.
Saito K; Uebanso T; Maekawa K; Ishikawa M; Taguchi R; Nammo T; Nishimaki-Mogami T; Udagawa H; Fujii M; Shibazaki Y; Yoneyama H; Yasuda K; Saito Y
Sci Rep; 2015 Aug; 5():12466. PubMed ID: 26289793
[TBL] [Abstract][Full Text] [Related]
55. Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease.
Kefala G; Tziomalos K
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):189-191. PubMed ID: 30791762
[No Abstract] [Full Text] [Related]
56. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
[TBL] [Abstract][Full Text] [Related]
57. Total aralosides of aralia elata (Miq) seem (TASAES) ameliorate nonalcoholic steatohepatitis by modulating IRE1α-mediated JNK and NF-κB pathways in ApoE-/- mice.
Luo Y; Dong X; Yu Y; Sun G; Sun X
J Ethnopharmacol; 2015 Apr; 163():241-50. PubMed ID: 25655997
[TBL] [Abstract][Full Text] [Related]
58. Extracellular Vesicles as Messengers Between Hepatocytes and Macrophages in Nonalcoholic Steatohepatitis.
Schattenberg JM; Lee MS
Gastroenterology; 2016 Apr; 150(4):815-8. PubMed ID: 26924096
[No Abstract] [Full Text] [Related]
59. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
Gitto S; Guarneri V; Sartini A; Andreone P
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798
[TBL] [Abstract][Full Text] [Related]
60. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
